This agreement with ArmaGen expands Shire’s commitment to finding treatments for Hunter syndrome, which also includes SHP-609, Shire’s product currently being investigated to treat the CNS manifestations associated with Hunter syndrome. James Callaway, Ph.D., Chief Executive Officer of http://www.themarker.com/misc/1.595043 ArmaGen said, “Shire is the ideal partner for AGT-182, based on the company’s international reach and expertise in serving patients with Hunter syndrome. We look forward to beginning the Phase I/II clinical trial of AGT-182 in collaboration with Shire and leveraging their expertise with these patients.” About AGT-182 AGT-182, which has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is designed to take advantage of the body’s natural system for transporting products across the blood brain barrier (BBB) by using the same receptor that delivers insulin to the brain. AGT-182 is engineered by the fusion of the replacement IDS enzyme to an antibody that binds to a receptor on the BBB.
America’s Got Talent Live! Radio Contest – MyArkLaMiss.com – KTVE NBC 10 – KARD FOX 14 – Your homepage for the latest News, Weather and Sports in the ArkLaMiss!
BROADCAST DISCLAIMER IS NOT PART OF THE OFFICIAL RULES. Broadcast disclaimer example: NO PURCHASE NECESSARY. Void where prohibited. Open only to permanent, legal U.S. residents of the terrestrial broadcast signal geographic listening area of KTVE & KLIP who are 18 years or older. Begins July 22, 2014 and ends July 29, 2014. Prize restrictions apply. To enter and for official rules and prize details, go to Myarklamiss.com.
Calabasas Biotech Signs License Agreement | San Fernando Valley Business Journal
In exchange, Shire will receive worldwide commercialization rights for AGT-182. The collaboration will be managed by a joint steering committee with representatives from both companies. AGT-182 is ArmaGens main investigational drug, and the company plans to start clinical trials before the end of the year. Shire is the ideal partner for AGT-182, based on the companys international reach and expertise in serving patients with Hunter syndrome, James Callaway, chief executive of ArmaGen, said in a statement. Hunter syndrome is a rare, progressive and severe disorder in which the body cant break down complex sugars.